#reservoir

Gilead Sciences’ second round of cure grants supports these five research projects.

This Ohio researcher will be using CRISPR gene editing to target HIV, thanks to funding from The Campbell Foundation.

Apparently, the virus inhibits natural antiviral effects, the body’s first line of defense, and manipulates them to persist indefinitely.

Cure studies typically require a temporary break in HIV treatment, often with little promise of a personal benefit to the participant.

The 13 new grants support innovative approaches such as gene therapy.

However, the drug does not reduce the size of the reservoir.

This finding adds yet another degree of complexity to the byzantine puzzle that is the search for a cure for the virus.

An amfAR grant goes to two University of Massachusetts scientists exploring a novel technique.

Researchers have found that in addition to CD4s, macrophage cells can harbor HIV even in the face of antiretroviral treatment.

Researchers may have answered a bedeviling chicken-or-egg question about the persistence of HIV during antiretroviral treatment.

Pharmaceutical giant Gilead Sciences has awarded over $22 million in grants for 12 HIV-cure-focused research projects.

Funding will support these 12 research- and community-based projects.

In a 111-person group of people treated for HIV, the average viral reservoir half-life was 12 years.

Campbell Foundation funds nontraditional avenues of research.

Yet another study has shown the extreme complexity of the viral reservoir, where HIV hides from ARV treatment, frustrating cure attempts.

Even when people with HIV have an undetectable viral load, the virus replicates in lymph nodes, which helps replenish the viral reservoir.